AstraZeneca pulls Imfinzi in bladder cancer, nearly one year after Phase 3 miss February 22, 2021 Auto Bot AstraZeneca, BioPharma, biopharma nl, cancer, FDA, Imfinzi, Pharma, United Kingdom 0 AstraZeneca is withdrawing U.S. marketing of Imfinzi in bladder cancer after the drug failed a study required as a condition of its 2017 accelerated approval. The drug’s other approvals in lung cancer are not affected.